. 2019 Sep 23;181(6):579–590. doi: 10.1530/EJE-19-0173
This work is licensed under a Table 1.
Clinical characteristics of the study population on statin therapy. Data are presented as mean ± s.d. or median (95% CI).
| Controls (n = 24) | Patients with statin therapy (n = 26) | P | Effect size | |
|---|---|---|---|---|
| Age (years) | 53.7 ± 6.6 | 54.3 ± 5.5 | 0.69 | 0.03 |
| BMI (kg/m2) | 30 ± 4.2 | 30 ± 3.9 | 0.9 | 0.01 |
| Waist circumference (cm) | 101.8 ± 11 | 101.8 ± 9.5 | 0.86 | 0.01 |
| Systolic BP (mmHg) | 124.7 ± 15.2 | 126 ± 10.9 | 0.7 | 0.00 |
| Diastolic BP (mmHg) | 79.7 ± 10.1 | 79.2 ± 6.1 | 0.91 | 0.00 |
| HbA1c (%) | 6 ± 0.7 | 6 ± 0.5 | 0.78 | 0.05 |
| Fasting glucose mg/dL | 99.1 ± 10.8 | 102.1 ± 12.8 | 0.42 | 0.00 |
| 30-min glucose mg/dL | 143.3 ± 31.1 | 153 ± 41.8 | 0.52 | 0.01 |
| 120-min glucose mg/dL | 155.4 ± 34.1 | 159.1 ± 31.5 | 0.65 | 0.71 |
| Fasting insulin microu/mL | 6.5 (6.85; 12.3) | 7.3 (6.22; 10.1) | 0.56 | 0.02 |
| 30-min insulin microu/mL | 33.7 (30.5; 48.2) | 30.2 (27.3; 43.8) | 0.48 | 0.01 |
| 120-min insulin microu/mL | 43.4 (43.4; 86.5) | 62.5 (37.1; 80) | 0.18 | 0.04 |
| Total cholesterol (mg/dL) | 199.8 ± 32.5 | 168.5 ± 22.4 | 0.001 | 0.16 |
| HDL cholesterol (mg/dL) | 44.1 ± 13.4 | 41.5 ± 10.5 | 0.64 | 0.03 |
| Triglycerides (mg/dL) | 78.7 (78.7; 122.2) | 143 (117; 168.8) | 0.15 | 0.19 |
| LDL cholesterol (mg/dL) | 131 ± 30.5 | 99.9 ± 23.2 | 0.001 | 0.25 |
| Sex (M/F) | 12/9 | 12/10 | 0.9 | 0.00 |
| HOMA-IR | 1.4 (0.77; 2.03) | 1.6 (0.79; 2.41) | 0.34 | 0.05 |
| ISI0-120 | 44.5 (43.1; 57) | 34.9 (31.6; 46.1) | 0.04 | 0.14 |
| IG30 | 0.78 (0.54; 1.26) | 0.59 (0.34; 0.52) | 0.19 | 0.11 |
| DI | 0.36 (0.27; 0.99) | 0.26 (0.17; 0.27) | 0.21 | 0.15 |
BMI, body mass index; BP, blood pressure; DI, disposition index; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment-insulin resistance; ISI0-120, insulin sensitivity index 0-120; IG30, insulinogenic index; LDL, low-density lipoprotein.